Heart and Vessels

, Volume 25, Issue 1, pp 1–6 | Cite as

Relation of oral 1α-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients

  • Tetsuya OgawaEmail author
  • Hideki Ishida
  • Mayuko Akamatsu
  • Nami Matsuda
  • Ayuko Fujiu
  • Kyoko Ito
  • Yoshitaka Ando
  • Kosaku Nitta
Original Article


The role of decreased active vitamin D levels on vascular calcification has not been elucidated in hemodialysis (HD) patients. The aim of the present study was to evaluate the relationship between progression of aortic arch calcification (AoAC) and prescribed dose of 1α-hydroxy vitamin D. The enrolled study subjects were 65 (40 men and 25 women) HD patients. Calcification of the aortic arch was semiquantitatively estimated with a score (AoACS) on plain chest radiology. Change in AoACS (ΔAoACS) was obtained by subtracting the baseline AoACS value from the follow-up AoACS value. The second assessment was performed from 2 years after the first determination. The nonprogressors (63.2 ± 14.5 years) were significantly younger than the progressors (68.2 ± 10.8 years) (P = 0.0419). In addition, prescribed dose of 1α-hydroxy vitamin D3 was significantly higher in the nonprogressors (125.5 ± 109.1 μg) than progressors (84.8 ± 81.1 μg) (P = 0.0371). Multiple regression analysis revealed prescribed dose of 1α-hydroxy vitamin D3 (β value = −0.324, P = 0.0051) as well as DBP (β value = −0.418, P = 0.007), serum levels of P (β value = 0.333, P = 0.006) and C-reactive protein (β value = 0.237, P = 0.0048) to be significant independent determinants of ΔAoACS. In conclusion, the evaluation of AoACS on chest radiography is a very simple tool in HD patients. Active vitamin D therapy seems to protect patients from developing vascular calcification.

Key words

Aortic arch calcification Chest radiography Vitamin D Hemodialysis Cardiovascular disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ (2005) Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998–1999. J Am Soc Nephrol 16: 489–495CrossRefPubMedGoogle Scholar
  2. 2.
    Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17(12 suppl 3):S267–S273CrossRefPubMedGoogle Scholar
  3. 3.
    Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701CrossRefPubMedGoogle Scholar
  4. 4.
    Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM (2000) Phosphate regulations of vascular smooth muscle cell calcification. Circ Res 87:E10–E17PubMedGoogle Scholar
  5. 5.
    Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H (2001) Vascular calcification and inorganic phosphate. Am J Kidney Dis 38(4 suppl 1):S34–S37CrossRefPubMedGoogle Scholar
  6. 6.
    Guerin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcification in end-stage renal disease. Nephrol Dial Transplant 15:1014–1021CrossRefPubMedGoogle Scholar
  7. 7.
    Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535–541PubMedGoogle Scholar
  8. 8.
    Pan N-H, Yang H-Y, Hsieh M-H, Chen Y-J (2008) Coronary calcium score from multislice computed tomography correlates with QT dispersion and left ventricular wall thickness. Heart Vessels 23:155–160CrossRefPubMedGoogle Scholar
  9. 9.
    Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS, Ledingham JG (1993) Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 43:700–705CrossRefPubMedGoogle Scholar
  10. 10.
    Tabata T, Suzuki R, Kikunami K, Matsushita Y, Inoue T, Okamoto T, Miki T, Nishizawa Y, Morii H (1986) The effect of 1α-hydroxyvitamin D3 on cell-mediated immunity in hemodialyzed patients. J Clin Endocrinol Metab 63:1218–1221CrossRefPubMedGoogle Scholar
  11. 11.
    Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F (1998) Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037–2040CrossRefPubMedGoogle Scholar
  12. 12.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456CrossRefPubMedGoogle Scholar
  13. 13.
    Ogawa T, Ishida H, Matsuda N, Fujiu A, Matsuda A, Ito K, Ando Y, Nitta K (2009) Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int (in press)Google Scholar
  14. 14.
    Iribarren C, Sidney S, Sternfeld B, Browner WS (2000) Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 283:2810–2815CrossRefPubMedGoogle Scholar
  15. 15.
    Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N; Vascular Calcification Work Group (2004) Vascular calcification in chronic kidney disease. Am J Kidney Dis 43:572–579CrossRefPubMedGoogle Scholar
  16. 16.
    Witteman JC, Kannel WB, Wolf PA, Grobbee DE, Hofman A, D’Agostino RB, Cobb JC (1990) Aortic calcified plaques and cardiovascular disease (the Framingham Study). Am J Cardiol 66:1060–1064CrossRefPubMedGoogle Scholar
  17. 17.
    Witteman JC, Kok FJ, van Saase JL, Valkenburg HA (1986) Aortic calcification as a predictor of cardiovascular mortality. Lancet 2:1120–1122CrossRefPubMedGoogle Scholar
  18. 18.
    Li J, Galvin HK, Johnson SC, Langston CS, Sclamberg J, Preston CA (2002) Aortic calcification on plain chest radiography increases risk for coronary artery disease. Chest 121:1468–1471CrossRefPubMedGoogle Scholar
  19. 19.
    Salgueira M, del Toro N, Moreno-Alba (2003) Vascular calcification in the uremic patient: a cardiovascular risk? Kidney Int 63(Suppl 85):S119–S121CrossRefGoogle Scholar
  20. 20.
    Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A (1998) Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 18:404–410CrossRefPubMedGoogle Scholar
  21. 21.
    Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK (1999) Intravenous calcitriol regress myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33:73–81CrossRefPubMedGoogle Scholar
  22. 22.
    Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E (2006) Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 21:484–490CrossRefPubMedGoogle Scholar
  23. 23.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D (2005) 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sesipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20:1370–1377CrossRefPubMedGoogle Scholar
  24. 24.
    Teng M, Wolf M, Ofsthum MN, Lazarus MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125CrossRefPubMedGoogle Scholar
  25. 25.
    Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 270:1858–1865CrossRefGoogle Scholar
  26. 26.
    Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA (2006) Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 318:90–98CrossRefPubMedGoogle Scholar
  27. 27.
    Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771–780CrossRefPubMedGoogle Scholar
  28. 28.
    Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM (2007) Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860–866CrossRefPubMedGoogle Scholar
  29. 29.
    Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y (2004) Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis patients. Nephrol Dial Transplant 19:179–184.CrossRefPubMedGoogle Scholar
  30. 30.
    Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B (2006) Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 17:S267–S273CrossRefPubMedGoogle Scholar
  31. 31.
    London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metvier F (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613–620CrossRefPubMedGoogle Scholar
  32. 32.
    Spiegel DM, Raggi P, Smits G, Block GA (2007) Factors associated with mortality in patients new to haemodilaysis. Nephrol Dial Transplant 22:3568–3572CrossRefPubMedGoogle Scholar
  33. 33.
    Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945–1953CrossRefPubMedGoogle Scholar
  34. 34.
    National Kidney Foundation (2003) KDOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):1–201Google Scholar

Copyright information

© Springer Japan 2010

Authors and Affiliations

  • Tetsuya Ogawa
    • 1
    Email author
  • Hideki Ishida
    • 2
  • Mayuko Akamatsu
    • 1
  • Nami Matsuda
    • 1
  • Ayuko Fujiu
    • 1
  • Kyoko Ito
    • 2
  • Yoshitaka Ando
    • 2
  • Kosaku Nitta
    • 1
  1. 1.Department of Medicine, Kidney CenterTokyo Women’s Medical UniversityTokyoJapan
  2. 2.Hidaka HospitalGunmaJapan

Personalised recommendations